BioSyent has been growing earnings at an average annual rate of 12.9%, while the Pharmaceuticals industry saw earnings growing at 10.7% annually. Revenues have been growing at an average rate of 11.7% per year. BioSyent's return on equity is 20.1%, and it has net margins of 19.7%.
Key information
12.88%
Earnings growth rate
15.71%
EPS growth rate
Pharmaceuticals Industry Growth
5.95%
Revenue growth rate
11.66%
Return on equity
20.09%
Net Margin
19.65%
Last Earnings Update
31 Mar 2026
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How BioSyent makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
OTCPK:BIOY.F Revenue, expenses and earnings (CAD Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 26
46
9
23
0
31 Dec 25
43
9
22
0
30 Sep 25
42
9
21
0
30 Jun 25
40
8
20
0
31 Mar 25
38
8
20
0
31 Dec 24
35
7
19
0
30 Sep 24
35
7
19
0
30 Jun 24
34
7
19
0
31 Mar 24
33
7
18
0
31 Dec 23
32
6
18
0
30 Sep 23
31
6
18
0
30 Jun 23
29
5
17
0
31 Mar 23
27
5
16
0
31 Dec 22
28
5
16
0
30 Sep 22
28
6
15
0
30 Jun 22
28
6
14
0
31 Mar 22
28
6
14
0
31 Dec 21
29
6
14
0
30 Sep 21
27
5
14
0
30 Jun 21
26
4
15
0
31 Mar 21
24
4
13
0
31 Dec 20
22
4
12
0
30 Sep 20
22
4
11
0
30 Jun 20
23
5
11
0
31 Mar 20
23
5
11
0
31 Dec 19
21
4
10
0
30 Sep 19
22
5
10
0
30 Jun 19
21
5
10
0
31 Mar 19
22
6
10
0
31 Dec 18
22
6
10
0
30 Sep 18
22
5
10
0
30 Jun 18
22
6
10
0
31 Mar 18
21
5
10
0
31 Dec 17
21
5
10
0
30 Sep 17
20
5
9
0
30 Jun 17
19
5
9
0
31 Mar 17
18
4
8
0
31 Dec 16
18
4
8
0
30 Sep 16
17
4
8
0
30 Jun 16
17
4
8
0
31 Mar 16
16
4
8
0
31 Dec 15
15
4
7
0
30 Sep 15
15
4
6
0
Quality Earnings: BIOY.F has high quality earnings.
Growing Profit Margin: BIOY.F's current net profit margins (19.7%) are lower than last year (20.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BIOY.F's earnings have grown by 12.9% per year over the past 5 years.
Accelerating Growth: BIOY.F's earnings growth over the past year (15.5%) exceeds its 5-year average (12.9% per year).
Earnings vs Industry: BIOY.F earnings growth over the past year (15.5%) exceeded the Pharmaceuticals industry -4.8%.
Return on Equity
High ROE: BIOY.F's Return on Equity (20.1%) is considered high.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/07 14:17
End of Day Share Price
2026/07/07 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioSyent Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.